CClinicalTrials.gg
Not yet recruitingNCT07384286BRIGHTUpdated Aug 19, 2026

Behavioral Reinforcement Intervention for Greater Health Trajectories After Childhood Cancer (BRIGHT)

An interventional study of Lifestyle Management in Survivors of Childhood Cancer, sponsored by Vastra Gotaland Region. Not yet recruiting at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-19.

Sponsored by Vastra Gotaland Region · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
900
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Survivors of childhood cancer have a substantially increased risk of long-term health problems in adulthood, including cardiovascular disease, metabolic disorders, psychological morbidity, and impaired health-related quality of life (HRQoL). These risks are partly related to cancer treatment exposures but are also strongly influenced by modifiable lifestyle factors such as physical activity, diet, body weight, and cardiometabolic risk factors. Although healthy lifestyle behaviors are known to reduce morbidity and mortality in this population, many adult childhood cancer survivors do not meet current lifestyle recommendations and rarely receive structured, tailored support to change health behaviors.

The Behavioral Reinforcement Intervention for Greater Health Trajectories (BRIGHT) study aims to evaluate whether a person-centered, remotely delivered lifestyle intervention can improve health-related quality of life and key health markers in adult survivors of childhood cancer with an unhealthy lifestyle. The intervention focuses on increasing physical activity and improving dietary habits through structured video-based coaching delivered by trained health promoters over a 26-week period.

BRIGHT is conducted within NOPHO-CARE Sweden, a national population-based cohort of childhood cancer survivors, and uses a register-based randomized controlled design with two randomization steps. First, eligible participants are randomized to be offered the intervention or not, enabling evaluation of the population-level effect of offering the intervention through long-term register-based follow-up. Second, participants who consent to active participation are randomized to immediate or delayed start of the intervention, allowing controlled assessment of short-term intervention effects.

The primary research question is whether the BRIGHT lifestyle intervention leads to a clinically meaningful improvement in health-related quality of life, measured by the PROPr utility index derived from PROMIS-29, compared with a control period. Secondary questions address whether the intervention improves physical activity, cardiorespiratory fitness, muscle strength, diet quality, body weight, blood pressure, and cardiometabolic and biological markers, including epigenetic age acceleration. The study also examines feasibility, adherence, and scalability of delivering a person-centered lifestyle intervention within a national survivorship follow-up structure.

In addition, BRIGHT investigates whether offering the intervention to the full eligible population leads to long-term reductions in cardiovascular disease, metabolic disease, psychiatric morbidity, and mortality, using national health registers. By combining individual-level efficacy and population-level effectiveness within a single study framework, BRIGHT aims to generate robust evidence to inform future preventive care and long-term follow-up strategies for adult survivors of childhood cancer.

Read the detailed description

Survival after childhood cancer has improved substantially, resulting in a growing population of adults exposed to cancer treatment early in life. Adult survivors of childhood cancer are at markedly increased risk of long-term adverse health outcomes, including cardiovascular disease, cardiometabolic disorders, psychological morbidity, and reduced health-related quality of life (HRQoL). While treatment-related factors contribute to these risks, modifiable lifestyle behaviors-particularly physical activity, diet, and body weight-play a central role in shaping long-term health trajectories. Evidence indicates that healthy lifestyle behaviors may yield even greater absolute risk reduction in childhood cancer survivors than in the general population. However, many survivors do not meet recommended lifestyle guidelines and are rarely offered structured, tailored, and sustained behavioral support within routine follow-up care.

The Behavioral Reinforcement Intervention for Greater Health Trajectories (BRIGHT) study is designed to evaluate a person-centered, remotely delivered lifestyle intervention targeting physical activity and dietary habits in adult survivors of childhood cancer with an unhealthy lifestyle. The study is embedded within NOPHO-CARE Sweden, a national population-based survivorship cohort that integrates registry data, patient-reported outcomes, and biological samples. This infrastructure enables both short-term evaluation of intervention efficacy and long-term assessment of population-level effectiveness using national health registers.

Study Design Overview BRIGHT is a pragmatic, register-based randomized controlled trial employing a two-step randomization design to simultaneously address efficacy and real-world effectiveness. The first randomization occurs at the population level within NOPHO-CARE Sweden, where eligible individuals are randomized to be offered the intervention or not. This allows evaluation of the long-term health impact of offering a lifestyle intervention at scale, independent of individual uptake, using register-based follow-up.

The second randomization occurs among participants who consent to active participation in the intervention and study-specific assessments. These participants are randomized to immediate or delayed (waitlist) start of the intervention. This design enables controlled comparisons of short-term intervention effects while ensuring that all actively participating individuals eventually receive the intervention.

Study Population The study targets adult (≥18 years) survivors of childhood cancer who are participants in NOPHO-CARE Sweden and report an unhealthy lifestyle, defined as insufficient physical activity and/or overweight or obesity. Individuals with established cardiovascular disease or other medical conditions that would make participation unsafe are excluded from active participation. Eligibility is determined using existing cohort data and baseline assessments.

Intervention The BRIGHT intervention consists of a structured, person-centered lifestyle coaching program delivered entirely through video-based sessions. Participants engage in 16 scheduled sessions over a 26-week period with trained health promoters who have expertise in behavioral science and lifestyle change. Sessions are conducted weekly during the initial phase of the intervention and biweekly thereafter.

The intervention focuses on supporting participants to increase physical activity and improve dietary habits in line with international recommendations. Using a person-centered approach, participants and health promoters collaboratively identify individualized goals, barriers, and facilitators, and regularly review progress. The intervention emphasizes sustainable behavior change rather than short-term performance targets and is tailored to each participant's preferences, capacities, and life circumstances. The intervention does not include pharmacological treatment or medical decision-making and does not replace or modify routine healthcare.

Data Collection and Assessments Study-specific assessments are conducted remotely and primarily in participants' home environments, with guidance and oversight provided via video visits by research nurses. Assessments are performed at baseline, at follow-up points aligned with intervention timing, and at longer-term follow-up for trajectory analyses.

Data collection integrates:

  • Patient-reported outcomes, including health-related quality of life and lifestyle behaviors;
  • Objective measurements of physical activity, fitness, body composition, and blood pressure;
  • Functional performance tests conducted under video supervision;
  • Self-collected capillary blood samples for laboratory analyses of cardiometabolic and biological markers.

All methods used are validated, low-risk, and suitable for remote administration. Standardized protocols and quality control procedures are applied to ensure data reliability.

Outcomes and Follow-up The primary objective of BRIGHT is to determine whether participation in the lifestyle intervention results in a clinically meaningful improvement in health-related quality of life compared with a control period. Secondary objectives address changes in physical activity, fitness, diet, cardiometabolic risk factors, and biological markers, as well as sustainability of effects over time.

Beyond individual-level outcomes, BRIGHT evaluates the long-term effectiveness of offering the intervention at the population level. Participants randomized in the first step are followed longitudinally through national health registers to assess incidence of cardiovascular disease, metabolic disease, psychiatric morbidity, healthcare utilization, and mortality. This approach enables evaluation of whether implementing a lifestyle intervention within a national survivorship follow-up structure translates into meaningful reductions in long-term disease burden.

Feasibility and Scalability An additional objective of BRIGHT is to assess feasibility, adherence, and scalability of delivering a person-centered lifestyle intervention within a national cohort. Metrics such as uptake, retention, adherence to intervention sessions, and completion of assessments are examined to inform future implementation. By embedding the trial within NOPHO-CARE Sweden, BRIGHT evaluates delivery under real-world conditions rather than in a highly selected research setting.

Safety and Ethical Considerations BRIGHT is designed as a minimal-risk behavioral intervention. Physical assessments are conducted under professional supervision via video, with predefined safety criteria and procedures for managing abnormal findings. Participants with clinically concerning measurements are advised to seek routine medical care, but no clinical treatment decisions are made within the study.

All data are pseudonymized and stored in secure research environments in accordance with national and European data protection regulations. Analyses are conducted within protected systems that prevent export of individual-level data. Results are reported only in aggregate form.

Significance BRIGHT is the first national register-based randomized controlled trial in Sweden to evaluate a fully remote, person-centered lifestyle intervention in adult survivors of childhood cancer. By combining individual-level efficacy evaluation with population-level effectiveness assessment, the study aims to generate robust evidence to inform preventive strategies and long-term follow-up care. If successful, BRIGHT may provide a scalable model for integrating structured lifestyle support into survivorship care for childhood cancer survivors at the national level.

02

Conditions studied

  • Survivors of Childhood Cancer

Keywords

  • Lifestyle
  • Survivors of childhood cancer
03

In context

Lead sponsor

Vastra Gotaland Region is the lead sponsor of 267 studies on the registry; 107 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Participant in NOPHO-CARE Sweden
  • Performing \<150 min moderate-vigorous physical activity per week and/or body mass index 28-35.

Exclusion criteria

Exclusion Criteria:

  • Pre-existing diagnosis of heart failure or coronary artery disease
  • Uncontrolled hypertension, defined as >180/100 mmHg
  • Other medical reasons that the intervention or outcome assessments are considered unsafe (as decided by a study physician)
  • Inability to perform the intervention or outcome assessments due to lack of mobile device (computer, tablet or telephone) with internet access or language barriers.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
900 participants (estimated)

Study arms

  • No intervention
    Register-based follow-up

    Participants in NOPHO-CARE Sweden who are randomized to not being contacted regarding BRIGHT but will only undergo register-based follow-up within NOPHO-CARE Sweden

  • Active comparator
    Waitlist control with cross-over

    Active participation in BRIGHT. Randomized to waitlist control and start of intervention after 6 months.

    Behavioral: Lifestyle Management

  • Experimental
    Immediate intervention

    Active participation in BRIGHT and randomized to immediate start of the intervention.

    Behavioral: Lifestyle Management

Interventions

  • BehavioralLifestyle Management

    Person-centered lifestyle support

06

What researchers measure

Primary outcomes

  1. Health-related quality of life

    The primary outcome will be change in HRQoL using the PROPr utility index, derived from patient-reported outcome measures information system (PROMIS)-29.

    Time frame: from Baseline until 6 months

Secondary outcomes

  1. Physical activity

    Physical activity will be measured by triaxial accelerometers (Axivity, model AX3).

    Time frame: From baseline until six months for comparison between groups and until 18 months for trajectories.

  2. Cardiorespiratory fitness

    Cardiorespiratory fitness will be estimated using the 2-minute step test

    Time frame: From baseline until six months for comparison between groups and until 18 months for trajectories.

  3. Handgrip strength

    Grip strength will be measured with the Jamar Plus+ dynamometer

    Time frame: From baseline until six months for comparison between groups and until 18 months for trajectories.

  4. Lower limb strength

    Lower limb strength will be tested with the Chair Rise-5 repetitions

    Time frame: Change from baseline until six months for comparison between groups and until 18 months for trajectories.

  5. Diet

    Riksmaten Flex questionnaire

    Time frame: Change from baseline until six months for comparison between groups and until 18 months for trajectories.

  6. Body mass index

    Body weight will be assessed with a provided digital Seca 807 scale. Weight will be assessed after voiding, during a video meeting with a research nurse. The research nurse will ensure participants use the scale on a hard surface and follow standardized weighing procedures to minimize measurement variability. Body height will be taken from clinical information from outpatient clinic visits, registered in the Swedish Childhood Cancer Registry.

    Time frame: From baseline until six months for comparison between groups and until 18 months for trajectories.

  7. Blood pressure

    Blood pressure will be done according to best practices for home-based blood pressure monitoring.

    Time frame: Change from baseline until six months for comparison between groups and until 18 months for trajectories.

  8. Patient-reported outcome measures

    Patient-reported outcomes of fatigue, sleep, and pain, reported with PROMIS-29.

    Time frame: Change from baseline until six months for comparison between groups and until 18 months for trajectories.

  9. Glucose metabolism

    Assessed with HbA1c from dried blood spots.

    Time frame: Change from baseline until six months for comparison between groups and until 18 months for trajectories.

  10. Lipid metabolism

    Total cholesterol, HDL, LDL, triglycerides, and apolipoproteins from dried blood spots.

    Time frame: Change from baseline until six months for comparison between groups and until 18 months for trajectories.

  11. Metabolic profiles of diet intake

    Untargeted metabolomics from dried blood spots will be analyzed.

    Time frame: Change from baseline until six months for comparison between groups and until 18 months for trajectories.

  12. Epigenetic age acceleration

    Epigenetic age acceleration will be assessed from epigenetic clocks from DNA extracted from dried blood spots.

    Time frame: Change from baseline until six months for comparison between groups and until 18 months for trajectories.

  13. Cardiometabolic, cardiovascular, and psychiatric morbidity

    Will be assessed from register-based follow-up of randomization 1.

    Time frame: From end of intervention until 2, 5, and 10 years.

  14. Mortality

    From register-based follow-up of randomization 1.

    Time frame: From end of intervention until 5 and 10 years.

  15. Health economics

    Health economic evaluation of the intervention, using information from EQ-5D-5L and actual healthcare costs from register-based follow-up.

    Time frame: Until 5 years after randomization 1.

07

Study locations

1 site
  • Centrum för livsstilsintervention
    Gothenburg, Sweden
    • Aron Onerup, MD, PhD · Contact · aron.onerup@gu.se · +46313421000
    • Aron Onerup, MD, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided — Not decided yet.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07384286
Lead sponsor
Vastra Gotaland Region
Collaborators
Göteborg University
Responsible party
Sponsor
First posted
Feb 3, 2026
Start date
Oct 2026 (estimated)
Primary completion
Dec 2030 (estimated)
Completion
Dec 2030 (estimated)
Last update
Aug 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion